| The Ivy for Friday, April 26, 2024
| | | | | | Down We Go? Yesterday, we discussed how the market had shown relative strength recently and asked the question whether the bullish sentiment would last. While it's hard to know precisely when a bottom will take place, we highlighted the danger of trying to pick the low point because inevitably at some stage betting on the bottom will lead to a losing trade where lower lows follow. We also emphasized that the approach successful traders take is to adhere to technical trends, which is definitively down. Look no further than the chart below to see the trend. Get the full details here | | | | | |
Ivy Content You May Have Missed | | | | | | In the wake of a recent market selloff, the financial landscape showed signs of recovery, hinting at potential seller exhaustion, a development that may suggest a pivotal shift in where the market goes next. Amid the volatility, several key economic indicators and corporate earnings reports loom large on the horizon, so will the bullish sentiment hold? Get the full details here
| | | | | |
| | | | | | Is It Time To Sell? Knowing when to sell may feel like rocket science if you're new to investing but it can be quite simple. While technicians may bamboozle you with indicators and fancy signals, the best traders in the world keep it straightforward. Take for example one champion trader who went short the market recently. At a glance of a regular chart, it may not be obvious why the timing is so clear. Can you spot the perfect day in the chart below? Get the full details here | | | | | |
| | | | | | Is This Little-Known Health Innovation The Next Big Thing? It's hard to find the next big thing but Exact Sciences might be as close as any company is to it via its liquid biopsies, a transformative approach to diagnosing and monitoring various diseases by detecting signs of cancer, genetic anomalies, or other conditions in blood or other bodily fluids. This technology has been particularly promising for cancer, where it has the potential to improve early detection and treatment monitoring through a simple blood draw. These tests sample of blood for tiny bits of DNA that are shed by cancer cells and reveal whether someone has cancer, at what progression. Get the full details here | | | | | |
- G. O'Fiachra We value your feedback: Please let us know what you think about our investing ideas so far, and any recommendations you may have for increasing the value of this newsletter. Please follow this link for a quick, 2-minute survey You Might Also Like:  |
|
| | Advertising Disclosure: This email may contain paid advertisements. Summa Money publishes 4 newsletters with various areas of focus. The Ivy is delivered 3x per week with a focus on investments that could generate passive income. The Burst is delivered 2x per week with a focus on growth stocks. The Spotlight is delivered 1x per week with a focus on high potential stocks and economic insights. The Daily is an occasional newsletter with a focus on the best investing stories and news from around the world. We hope you enjoy them all, but feel free to unsubscribe from the content you do not want to receive. If you do not wish to receive this email, then we apologize for the inconvenience. You can immediately discontinue receiving this email by clicking the unsubscribe link at the bottom of this email. If you have any questions, please send an email with your questions to support@summamoney.com. Nothing in this email should be considered personalized financial advice. We strongly urge you to read our full disclaimer here. If you can't see this message, view it in your browser. You are receiving this e-mail at punjabsvera@gmail.com as a part of your free subscription to the Ivy Newsletter. To read our privacy policy follow this link. or To unsubscribe by mail, write us at: Summa Money | 2319 N Andrews Ave. Fort Lauderdale, FL 33311 Website: Summa Money Nothing in this email should be considered personalized financial advice. Staff members at Summa Money are not qualified to answer your investing-related questions as they are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Copyright 2024 Summa Money. All rights reserved. Advertise With Us |
|
|
In order to unsubscribe from this mailing list, please click
here 
